Listen to the podcast or read the article below.
In emerging markets, much of the focus has recently gone to China and, with it, other Asian economies. China was first in and first out of the pandemic and its strong recovery from the effects of lockdowns and other epidemic-fighting constraints has been solid and has emanated to other economies in the region. Elsewhere, the performance of emerging markets has been more diverse, in part due to the initially less successful rollout of vaccines in many countries.
Before we look at regional performance, it is important to stress that the effects of the pandemic on the portfolio were limited. Early on, as the Chinese city of Wuhan went into lockdown, we were able to reduce our exposure to travel-related stocks.
With the recovery and the rollout of vaccines, some of these stocks are still trading at levels that do not fully reflect the underlying fundamentals. So, we are beginning to see opportunities there. As long-term investors, we expect many companies to benefit from the large-scale stimulus measures and supportive government policies around the world for many years ahead. That includes the obvious recovery plays, for example, the travel-related industries.
Emerging markets: More than just Asia
While it is true the issues around the vaccine rollouts may have held back the performance of the overall emerging market index, it is up by 7% so far this year. On a year-on-year basis, it is up a healthy 41%. We believe it has further to go.
Before we go into the prospects, let’s now take a closer look at regional performance. Non-Asian regions such as Latin America, eastern Europe and South Africa have outperformed Asian regions so far this year. They are up by some 15% (see exhibit 1).
This underscores the fact that the emerging market complex covers a wealth of countries that should not all be tarred with the same brush and that deserve an individual assessment, both in terms of the risks, but also very much in terms of the opportunities.
Diversification: Seizing the opportunities
Investors should note that the broad emerging market index covers more than 25 countries and some 2 000 companies. If you are a passive investor and invest in just the index, you are effectively focusing on the top 15 companies, making up 30% of the index. That is quite a concentrated holding. We believe there is room for a broader perspective. To get the full benefit of the 1 000-odd opportunities, you need to be an active manager.
The recent rotation into value stocks has only amplified those opportunities (emerging markets are typically associated with a growth profile). We believe the growth to value/cyclical rotation will likely persist in the medium term, particularly as interest rates rise.
At a portfolio level, we have seen a rebound in commodities companies as prices rise amid the cyclical recovery of many economies and we believe they have further to go since they are still trading at a discount. Again, if you were to invest just in the index, you would miss out on such opportunities since these companies make up only a small part of the MSCI EM.
Tackling the risks: Diversification
It is fair to say that investing in emerging markets is often associated with geopolitical risk, but we believe the uncertainties can be navigated by means of constant diversification across countries. A further element in managing these risks is to assess each country case-by-case for issues such as capital controls, market liquidity and debt sustainability.
Since there are more than 25 countries in this complex, we believe there are plenty of opportunities to avoid countries where there is a lot of geopolitical uncertainty. Again, this means you need to manage the portfolio actively to generate alpha.
A final attraction: Undervaluation
Apart from diversification benefits, we believe valuations are currently attractive. The price-earnings ratio for the MSCI Emerging Markets index is at 14x. That is a discount to the MSCI World, which is at 20x, the US S&P500 at 21x and the US NASDAQ at 27x (see exhibit 2).
Emerging markets are home to some of the most innovative and largest companies in the world. So, from that perspective, the asset class is also trading at a discount to the MSCI EM’s long-term growth profile and the solid fundamentals.
This undervaluation relative to many developed markets leaves us quite optimistic about the outlook for the asset class over the next three to four years. We are focused on uncovering idiosyncratic opportunities, including attractively valued quality growth compounders, mispriced growth opportunities, and special situations as they arise.
Any views expressed here are those of the author as of the date of publication, are based on available information, and are subject to change without notice. Individual portfolio management teams may hold different views and may take different investment decisions for different clients. This document does not constitute investment advice.
The value of investments and the income they generate may go down as well as up and it is possible that investors will not recover their initial outlay. Past performance is no guarantee for future returns.
Investing in emerging markets, or specialised or restricted sectors is likely to be subject to a higher-than-average volatility due to a high degree of concentration, greater uncertainty because less information is available, there is less liquidity or due to greater sensitivity to changes in market conditions (social, political and economic conditions).
Some emerging markets offer less security than the majority of international developed markets. For this reason, services for portfolio transactions, liquidation and conservation on behalf of funds invested in emerging markets may carry greater risk.